Immunotech Laboratories Inc. (IMMB)
EXPM EXPM Primary Summary
Immunotech Laboratories Inc. (IMMB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunotech Laboratories Inc. ever had a stock split?
Immunotech Laboratories Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Jennifer L. Bath CEO | EXPM Exchange | 45254F203 CUSIP |
| US Country | 4 Employees | - Last Dividend | 26 Feb 2009 Last Split | - IPO Date |
Overview
Immunotech Laboratories, Inc. is at the forefront of developing innovative therapeutic solutions for combating life-threatening viral diseases, with a primary focus on HIV/AIDS and Hepatitis. Specializing in proprietary proteins, the company has pioneered a flagship compound, ITV-1, which has demonstrated significant potential in modulating the immune system and treating various immuno-related disorders. Located in Monrovia, California, Immunotech operates under the umbrella of Eco-Petroleum Solutions, Inc., marking a strategic alliance aimed at leveraging synergies between their respective technological advances and research capabilities. This collaboration underscores the company’s commitment to advancing healthcare solutions that can make a substantial impact on global health challenges.
Products and Services
- ITV-1 (Immune Therapeutic Vaccine)
ITV-1 stands at the core of Immunotech Laboratories' innovative approach to combating significant viral diseases like HIV/AIDS and Hepatitis C. This breakthrough therapy is a suspension of irreversible pepsin fraction (IPF), a proprietary compound designed to modulate the immune system. By targeting the intricate mechanisms of the immune response, ITV-1 offers a promising treatment pathway for patients suffering from these chronic conditions. The potential of ITV-1 extends beyond mere treatment; it is a beacon of hope for enhancing quality of life and longevity for affected individuals worldwide.
- Immune System Modulation
Aside from its primary applications in treating HIV/AIDS and Hepatitis C, Immunotech's proprietary technologies, including ITV-1, serve a vital role in immune system modulation. This encompasses a broader spectrum of immuno-related disorders, providing a versatile platform for addressing a variety of health challenges. By fine-tuning the immune response, Immunotech aims to offer therapeutic benefits across multiple disease states, reinforcing its position as a leader in immune-focused healthcare innovation.
